Medexus Fully Repays Convertible Debentures In Cash At Maturity
Ontario and Chicago, Illinois--(Newsfile Corp. - October 16, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has made in cash the final maturity date payment of C$51.1 million (or approximately US$37.5 million) to Computershare Trust Company of Canada as trustee for holders of Medexus's 6% unsecured convertible debentures due October 16, 2023 (TSX: MDP.DB). Under the terms of the indenture governing the convertible debentures, each holder will be entitled to receive from the trustee...
2023-10-16 7:00 AM EDT
Medexus Announces Closing of C$10 Million Bought-Deal Public Offering
Ontario and Chicago, Illinois--(Newsfile Corp. - October 6, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the closing of its bought-deal public offering of 3,389,900 units (Units) at a price of C$2.95 per Unit for aggregate gross proceeds to Medexus of C$10,000,205 (Offering). The net proceeds from the Offering, after deducting underwriting discounts and commissions and offering expenses, will be used for working capital and general corporate purposes, which...
2023-10-06 9:43 AM EDT
Medexus and medac Agree to Amend US Treosulfan Agreement
Ontario and Chicago, Illinois--(Newsfile Corp. - September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a third amendment to its February 2021 exclusive license agreement with medac GmbH relating to commercialization of treosulfan in the United States.Among other things, the third amendment extends the agreed outside date for FDA approval to reflect the current status of the FDA regulatory review process, and...
2023-09-28 7:34 PM EDT
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 9, 2023 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the company's...
2023-09-21 5:00 PM EDT
Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility
Ontario and Chicago, Illinois--(Newsfile Corp. - September 5, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into an amendment to the company's senior secured credit agreement with BMO as agent and lender. The amendment provides for a US$18 million increase in BMO's term loan commitment under the existing facility's previously disclosed accordion feature, among other amendments. Medexus intends to apply the full US$18 million, net of any transaction expenses, toward...
2023-09-05 7:30 AM EDT
Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B
Ontario and Chicago, Illinois--(Newsfile Corp. - August 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced the presentation of data from a Phase 3/4 study that evaluated the pharmacokinetics (PK), safety, and efficacy of IXINITY, an intravenous recombinant factor...
2023-08-17 5:30 PM EDT
Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million
Ontario and Chicago, Illinois--(Newsfile Corp. - August 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, 2023 (the company's fiscal Q1 2024). All dollar amounts...
2023-08-09 5:30 PM EDT
Medexus to Participate in Fireside Chat at SHARE Series Event
Ontario and Chicago, Illinois--(Newsfile Corp. - August 4, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will present at the SHARE Series event on Monday, August 14, 2023 at 8:30 AM Eastern time.Event: SHARE SeriesDate: August 14, 2023Location: Virtual PresentationMedexus Presentation: Monday, August 14 at 8:30 AM Eastern timeKen d'Entremont, Medexus's Chief Executive Officer, and Marcel Konrad, Medexus's Chief Financial Officer, will...
2023-08-04 7:00 AM EDT
Medexus Schedules First Fiscal Quarter 2024 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - August 2, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 10, 2023 to discuss Medexus's results for its first fiscal quarter ended June 30, 2023. Medexus expects to file its financial statements and MD&A after markets close on August 9, 2023.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian and U.S. callers+1...
2023-08-02 7:00 AM EDT
Medexus Announces Preliminary Revenue for Fiscal Q1 2024
Ontario and Chicago, Illinois--(Newsfile Corp. - July 12, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company's fiscal quarter ended June 30, 2023 (the company's fiscal Q1 2024). All dollar amounts in this news release are in US dollars unless specified otherwise.Preliminary revenue estimates for fiscal Q1 2024The expected results discussed in this news...
2023-07-12 5:30 PM EDT
Medexus Generates Record Revenue of US$108.1 Million in Fiscal Year 2023
Ontario and Chicago, Illinois--(Newsfile Corp. - June 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2023 (the company's fiscal Q4 2023 and fiscal year 2023). All dollar amounts in this press release are in United States dollars unless specified otherwise.Financial highlightsRecord total revenue of $108.1 million in fiscal...
2023-06-21 5:40 PM EDT
FDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric Patients
Ontario and Chicago, Illinois--(Newsfile Corp. - June 15, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently accepted for review Medexus's supplemental Biological License Application (sBLA) for IXINITY® [coagulation factor IX (recombinant)] for the on-demand, prophylactic, and perioperative treatment of pediatric patients under 12 years of age with hemophilia B - a hereditary bleeding disorder characterized by a...
2023-06-15 7:25 AM EDT
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - June 14, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 22, 2023 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2023. Medexus expects to file its financial statements and MD&A after markets close on June 21, 2023.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian and...
2023-06-14 5:30 PM EDT
Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023
Ontario and Chicago, Illinois--(Newsfile Corp. - June 13, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to highlight positive new data on treosulfan that researchers at Toronto's Princess Margaret Hospital (PMH) recently presented at MDS 2023, the 17th annual International Congress on Myelodysplastic Syndromes, held in Marseille, France. The study, a retrospective analysis of patient outcomes, further confirms Medexus's optimism regarding treosulfan's potential positive...
2023-06-13 7:25 AM EDT
Medexus to Participate in the LD Micro Invitational XIII
Ontario and Chicago, Illinois--(Newsfile Corp. - June 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the LD Micro Invitational XIII from June 6-8 2023.Event: LD Micro Invitational XIIIDate: June 6-8, 2023Location: Luxe Sunset Boulevard Hotel, CaliforniaMedexus Presentation: Tuesday, June 6 at 2:30 PM Pacific timeKen d'Entremont, Medexus's Chief Executive Officer, and Marcel Konrad, Medexus's Chief Financial...
2023-06-01 5:30 PM EDT
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible Debentures
Ontario and Chicago, Illinois--(Newsfile Corp. - May 10, 2023) - Medexus Pharmaceuticals (TSX: MDP) (TSX: MDP.DB) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention...
2023-05-10 5:30 PM EDT
Medexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade Glioma
Ontario and Chicago, Illinois--(Newsfile Corp. - May 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today presented data demonstrating a 33% cost savings with Gleolan® (aminolevulinic acid HCl) oral solution, compared to conventional white light surgery, in US patients with high-grade glioma. The data were presented at ISPOR 2023, the annual meeting of the Professional Society for Health Economics and Outcomes Research (formerly known as the International Society for...
2023-05-09 6:21 PM EDT